All In Biotech

Drug Trial Radar · NCT06179511

Study of AZD9829 in CD123+ Hematological Malignancies

A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jan 31, 2024

Primary completion

Oct 31, 2025

Study completion Feb 24, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

Conditions

  • Hematological Malignancies

Interventions

  • AZD9829Drug

    AZD9829 will be administered by IV infusion

  • AZD9829Drug

    AZD9829 will be administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of dose limiting toxicities (DLTs).Time frame: Module 1 - 28 days.
  2. Safety evaluation of AZD9829: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: Module 1 - From informed consent until 60 days after last dose of AZD9829.
  3. Identify RP2D in R/R AML patients.Time frame: Moldule 1 -From informed consent until 60 days after last dose of AZD9829.

Locations

22 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Houston, Texas

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Heidelberg, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Tianjin, China

  • Research Site

    Frankfurt, Germany

  • Research Site

    Bologna, Italy

  • Research Site

    Kashiwa, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Yoshida-gun, Japan

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Salamanca, Spain

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.